



Greencosamine 750mg Tablet

Glucosamine HCl 750mg

Product Code :

Regn. No. : MAL10100036X

Description:

White coloured, plain, oval shaped film coated tablet.

Composition:

Each tablet contains Glucosamine Hydrochloride 750mg.

Pharmacodynamics:

Glucosamine metabolic actions on articular cartilage include the stimulation of proteoglycan synthesis by cultivated human chondrocytes and protection against the metabolic impairment induced by some NSAIDs in vitro. Glucosamine appears to affect specifically the synthesis of monomeric proteoglycan aggregates, since lower size proteoglycan identified by gel filtration on Sepharose Cl-2B only represent a minor portion of the total immunoreactive proteoglycan. In normal human adult chondrocytes in vitro, Glucosamine increases aggrecan protein mRNA.

Hellio et al recently observed that Glucosamine induced an increase of protein synthesis in human osteoarthritis chondrocytes in vitro. Based on these results, it is suggested that Glucosamine acts through an increase of sulphated glycosaminoglycans synthesis, which in turn, induces proteoglycan core protein production by human chondrocytes. Such an explanation is supported by the fact that Glucosamine stimulates SO4 uptake in rat articular cartilage in vitro. Similar results were also achieved in ex vivo experiments following treatment of animals for 14 days with oral Glucosamine. Analysed together, these experiments suggest that Glucosamine is able to stimulate glycosaminoglycans production and the synthesis of proteoglycan. Glucosamine has also showed in vitro anti-catabolic properties suppressing collagenase activity and increasing the diminished adhesion of chondrocytes to fibronectin in fibrillated cartilage. Glucosamine has been shown to possess anti-inflammatory activities in different in vivo animal models without inhibiting the synthesis of prostaglandins.

Pharmacokinetics:

The pharmacokinetics of glucosamine was investigated in 6 healthy male volunteers (2 per administration route) using radiolabelled ¹⁴C uniformly labelled glucosamine and administering it in single dose by intravenous

(i.v.), intramuscular (i.m.) or oral route. After oral administration, almost 90% of glucosamine was absorbed. Free glucosamine was not detectable in plasma. The radioactivity incorporated in plasmatic proteins followed similar pharmacokinetic patterns to those obtained after i.v. or i.m. administration, but plasmatic concentrations were smaller than the ones obtained after parenteral administration probably due to an effect of first hepatic pathway. Glucosamine reaches its plasmatic peaks approximately after 60 minutes and afterwards it descends rapidly. When comparing the AUC after oral administration with that obtained after endovenous administration, we observe that they are equivalent, with an absolute bioavailability of 72%. This is due to a notable absorption of glucosamine in the gastrointestinal tract which, considering 12.7% of fecal excretion of radioactivity, is 87% of the administered dose.

Indications:

As adjuvant therapy for osteoarthritis.

Recommended Dosage:

Light to Moderate Osteoarthritis Symptoms: Take 1 tablet once daily, 15 minutes before a meal for at least 6 weeks (or according to medical prescription).

Severe Osteoarthritis Symptoms:

Initial therapy: Take 1 tablet twice daily, 15 minutes before meals during a period of at least 8 weeks.

Follow-up Therapy: Take 1 tablet once daily, 15 minutes before a meal. Maintenance therapy should be followed for 3-4 months by administration of 1 tablet once daily.

Long-term Treatment: The treatment should be repeated every other 6 months or less according to medical prescription.

Glucosamine is a causal therapy and the therapeutic effect can be seen after approximately 1 week from the beginning. Therefore, in case of intense pains, it is advisable to take an anti-inflammatory drug in addition during the first days of treatment.

Route of Administration:

Oral

Contraindications:

Contraindicated in patients hypersensitive to glucosamine.

Warning & Precautions:

Glucosamine may increase insulin resistance. Those with type 2 diabetes and those who are overweight and have problems with glucose tolerance should have their blood sugars carefully monitored if they consume glucosamine. Because of insufficient data, children, pregnant women and lactating mothers should avoid using glucosamine.

Children: The medical literature has not reported any adverse effects related to glucosamine use in children. Since young children may have undiagnosed allergies or medical conditions, glucosamine should not be used in children under 12 years of age unless recommended by a physician.

Interactions with Other Medicines:

Glucosamine may increase the anti-inflammatory activity of NSAIDs such as Ibuprofen. This interaction may result in the need for lower doses of these medications.

Usage During Pregnancy And lactation:

Avoid usage in pregnant women and nursing mothers.

Side Effects / Adverse Reactions:

Cardiovascular: Peripheral oedema, tachycardia were reported in a few patients following larger clinical trials investigating oral administration in osteoarthritis. Causal relationship has not been established.

Central nervous system: Drowsiness, headache, insomnia have been observed rarely during therapy (less than 1%).

Gastrointestinal: Nausea, vomiting, diarrhea, dyspepsia or epigastric pain, constipation, heartburn and anorexia have been described rarely during oral therapy with glucosamine.

Skin: Skin reactions such as erythema and pruritus have been reported with therapeutic administration of glucosamine.

Symptoms and Treatment of Overdose:

No cases of accidental or intentional overdose are known. The animal acute and chronic toxicological studies indicate that toxic effects and symptoms of toxicity are not likely to occur, even after high overdoses.

Storage Conditions:

Keep in tightly closed container, below 30°C. Protect from light and moisture. Keep out of reach of children. *Jauhkan daripada capaian kanak-kanak.*

Shelf-life: 3 years

Pack Sizes: In containers of 10's, 20's, 30's, 40's, 50's or 60's. Not all pack sizes are marketed.

MAL Number: MAL10100036X

Marketed by:

Nuvanta Sdn Bhd
8th Floor, Wisma Consplant 1,
No.2, Jalan SS 16/4, 47500 Subang Jaya, Selangor, MALAYSIA.

Manufacturer and Product Registration Holder:

Unison Nutraceuticals Sdn Bhd
No.13, Jalan Tasik Utama 52, Kawasan Perindustrian Tasik Utama,
75450 Ayer Keroh, Melaka, MALAYSIA.

Date of Revision: 18/09/2025

